

## REPUBLIC OF THE PHILIPPINES

## DEPARTMENT OF HEALTH **BUREAU OF FOOD AND DRUGS**

Civic Drive, Filinvest Corporate City Alabang, Muntinlupa City Website: www.bfad gov.ph



08 January 2010

FDA CIRCULAR **2010**-002

SUBJECT: Declaring the Products Identified Below to be Imminently Injurious, Unsafe or Dangerous and Authorizing the FDA Inspectors to Seize Said Products from Public Sale or Distribution.

The Food and Drug Administration (FDA) have found, through laboratory examination that the samples of the following cosmetic products identified as:

a. Jiaoli Miraculuous Cream (Jiaoli)

b. Jiaoli Huichusu Special Cut Genuine (Jiaoli Huichusu)

c. Jiaoli 2+1 7 days Clearing Facial Spots Suit (Jiaoli),

which were collected on separate occasions at various establishments/outlets contain heavy metal (Mercury) exceeding the allowable limit of 1ppm Cosmetic products containing such impurities/contaminants that are way beyond the allowable limit are outright misbranded and the importation, distribution, selling or offering for sale of the same is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009. Further, the continued selling of such products in the market undeniably poses imminent danger or injury to the consuming public.

Accordingly, in the interest of protecting public health and safety and pursuant to Section 12 of Republic Act No. 9711 or the Food and Drug Administration Act of 2009 authorizing the seizure and holding in custody any health products found in violation of the provisions of the Act and other relevant laws, rules and regulations, the Food and Drug Regulation Officers of this Office are hereby ordered to seize immediately the above identified cosmetic products for custody from any outlets or establishments where they may be found. Any outlet or establishment found selling or offering for sale the above products must be reported immediately to the Legal, Information and Compliance Division, this Office for appropriate action.

> Maranta J. Jacandon RPh., MPA Acting Director IV